MARC details
| 000 -LEADER |
|---|
| fixed length control field |
06341ntm a2200337 i 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
12244737 |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20230824143141.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
160118s2015 ua dja frmb 000 0 eng c |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
EG-NcFUE |
| Description conventions |
rda |
| 041 0# - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
eng |
| Language code of summary or abstract/overprinted title or subtitle |
ara |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Edition number |
23 |
| Classification number |
615.19 |
| Item number |
A.A.A |
| 100 1# - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Abd EL Kader, Amira Mohsen. |
| Relator term |
author |
| 245 12 - TITLE STATEMENT |
|---|
| Title |
A Pharmaceutical Study on Oral Self-Nanoemulsifying Delivery System of Sertraline Hydrochloride for Enhanced Dissolution and Bioavailability / |
| Statement of responsibility, etc |
Amira Mohsen Abd EL Kader ; Supervised by Mahmoud M. Ghorab, Hussein O. Ammar. |
| 246 15 - VARYING FORM OF TITLE |
|---|
| Title proper/short title |
دراسة صیدلیة لصیاغة مستحلب نانومترى، عبر الفم، لعقار إیدروكلور السرترالین لزیادة معدل الذوبان و التوافر الحیوى / |
| 264 #1 - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) |
|---|
| Date of publication, distribution, etc |
2015. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
xiii, 7, 204 pages : |
| Other physical details |
illustrations ; |
| Dimensions |
30 cm. |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Source |
rdacontent |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
unmediated |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
volume |
| Source |
rdacarrier |
| 502 ## - DISSERTATION NOTE |
|---|
| Dissertation note |
Thesis (Ph.D.)-Cairo University, faculty of pharmacy, department of pharmaceutics, 2015. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc |
Includes bibliographical references. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc |
Depression is a prevalent psychiatric disorder with estimates reaching as<br/>high as 21%. For nearly 2,500 years, depression has been described as<br/>one of the most common illness of humankind, but only recently it has<br/>commanded major public health interest. It is manifested by a depressed<br/>mood, loss of pleasure in daily activities, sleep disturbances, cognitive<br/>difficulties and psychomotor disturbances.<br/>Depression is an important global public health problem due to both its<br/>relatively high lifetime prevalence and the significant disability that it<br/>causes. Without treatment, depression has the tendency to assume a<br/>chronic course, to recur, and to be associated with increasing disability<br/>over time.<br/>Currently, different classes of antidepressants are available, each with<br/>specific mechanism of action. Classes of antidepressants include,<br/>serotonin selective reuptake inhibitors, serotonin norepinephrine reuptake<br/>inhibitors, selective norepinephrine reuptake inhibitors, serotonin<br/>antagonist/reuptake inhibitors, tricyclic and tetracyclic antidepressants<br/>and many others.<br/>Sertraline HCl – a selective serotonin re-uptake inhibitor (SSRI) – is<br/>indicated for the treatment of depression and anxiety disorders, including<br/>obsessive-compulsive disorder, panic disorder and post-traumatic stress<br/>disorder. It is considered suitable for the treatment of depressive<br/>symptoms in elderly patients, including those with Alzheimer’s disease<br/>(AD), as it has minimal anticholinergic activity and is essentially devoid<br/>ii<br/>of cardiovascular effect. Furthermore, sertraline HCl may be useful in the<br/>management of other behavioural problems experienced by AD patients<br/>that are likely mediated by the serotonergic system, such as anxiety,<br/>irritability and aggression.<br/>Sertraline is administered orally in a daily dose of 50 mg. But various<br/>problems are associated with its oral delivery such as extensive first-pass<br/>metabolism, gastrointestinal disturbances such as nausea, dry mouth,<br/>diarrhea, decreased appetite etc., and ultimately its poor bioavailability<br/>(40–45%), which required this drug to be taken in high doses in order to<br/>maintain adequate plasma levels.<br/>Sertraline hydrochloride is practically insoluble in water. Its<br/>bioavailability is expected to be limited by its dissolution rate. To<br/>overcome these problems, various formulation strategies are exploited<br/>including the use of surfactants, lipids, permeation enhancers,<br/>micronisation, salt formation, cyclodextrin complexation, nanoparticles<br/>and solid dispersions.<br/>Most of the new drug candidates in development today are sparingly<br/>soluble and associated with poor bioavailability. In recent years, much<br/>attention has been focused on lipid-nanoemulsion formulations with<br/>particular emphasis on self-nanoemulsifying or self-emulsifying drug<br/>delivery systems (SNEDDS and SEDDS) to improve oral bioavailability<br/>of poorly water-soluble drugs.<br/>Oral-based drug delivery system is the most common way to deliver<br/>drugs into the blood stream. The water-soluble drugs can diffuse freely<br/>and easily in gastrointestinal tract and they have a high bioavailability.<br/>iii<br/>However, more and more drugs being discovered nowadays with the<br/>advances in biotechnology and pharmaceutical technology are oil-soluble.<br/>One way to deliver oil-soluble drugs is to incorporate the drug into an<br/>inert lipid vehicle, such as nanoemulsions, oils, surfactants, dispersions<br/>and liposomes.<br/>Nanoemulsions are isotropic, thermodynamically stable systems and the<br/>droplets of nanoemulsions are of very small size. Self-nanoemulsifying<br/>drug delivery system (SNEDDS) is a pre-mixture of drug, oil, surfactant<br/>and cosurfactant that can be used to deliver oil-based drugs. Upon gentle<br/>shaking and gastric juice dilution in stomach, it can form nanoemulsion<br/>spontaneously.<br/>Preparation of sertraline HCL formulation, presents a challenge in the<br/>development of an oral dosage form because of its poor solubility. In<br/>recent years, self-emulsified formulations gained more attention because<br/>of their ability to improve aqueous solubility and bioavailablity of a<br/>variety of drugs. SNEDDS formulations are normally prepared as liquids<br/>and dispensed in form of soft or hard gelatin capsule filled which give<br/>rise to some drawbacks such as interaction of the fill with the capsule<br/>shell, risks of leakage when they are filled into hard gelatin capsules and<br/>limited shelf-life. In recent years, there is a growing trend to formulate<br/>solid SNEDDS by adsorbing liquid SNEDDS onto suitable solid carriers.<br/>Such solid SNEDDS can be easily filled in capsules and overcome the<br/>disadvantages of liquid formulations described above and on oral<br/>administration, they readily form microemulsion in vivo; presenting the<br/>drug in nano-sized and ‘ready to absorb’ form. |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
Text in English, abstracts in English & Arabic. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Pharmaceutical chemistry |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Biotechnology |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Biopharmaceutics. |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Ghorab, Mahmoud M. , |
| Relator term |
Supervisor. |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Ammar, Hussein O. , |
| Relator term |
Supervisor. |
| 710 2# - ADDED ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
Cairo University. |
| Subordinate unit |
Faculty of Pharmacy. |
| -- |
Department of Pharmaceutics. |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Item type |
Thesis |